ArticlePLOS global public health2026
Protective factors against acute kidney injury in children exposed to diethylene glycol-contaminated medicines: A case-case-control analysis from The Gambia outbreak.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Substandard and Falsified Medicines, Regulatory Capacity and Public Health: A Narrative Review With a Focus on Africa.Public health challenges · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During The Gambia's 2022 diethylene glycol (DEG) outbreak, 82 children developed acute kidney injury (AKI) with 80% mortality. However, approximately 30% of children with documented DEG exposure did not develop AKI. Understanding protective factors could enable risk stratification and inform prophylactic interventions in future outbreaks. We conducted a case-case-control study among 321 children aged ≤8 years from six Gambian health regions. We compared exposed children who developed AKI (exposed-susceptible, n = 37) with exposed children who remained healthy (exposed-resistant, n = 16) and unexposed healthy children (n = 242). Multivariable logistic regression identified factors associated with AKI resistance among the 53 exposed children, adjusting for age, sex, and socioeconomic indicators. Sensitivity analyses included propensity score matching and stratification. Three factors were independently associated with reduced AKI risk: older age (adjusted OR=0.58 per year, 95% CI [0.36-0.92], p = .021), multivitamin supplementation (aOR=0.24, 95% CI [0.06-0.85], p = .028), and exposure to a single contaminated medicine (aOR=4.21 for ≥2 vs 1 medicine, 95% CI [1.12-16.85], p = .034). A dose-response relationship was observed, with AKI odds increasing 4-fold per additional contaminated medicine (p-trend = .018). Promethazine oral solution showed strongest toxicity (aOR=4.15, 95% CI [1.15-15.82]), consistent with highest DEG concentration (19.4 mg/mL). Multivitamin effects were strongest in children <18 months (aOR=0.15, 95% CI [0.02-0.81]). Findings remained robust across propensity score-matched analyses. Study limitations include small sample size of resistant children (n = 16), potential recall bias, wide confidence intervals, and possible residual confounding of multivitamin associations by socioeconomic and health literacy factors. Substantial heterogeneity exists in pediatric DEG susceptibility. Younger age, polypharmacy with multiple contaminated products, and absence of multivitamin supplementation were independently associated with increased AKI risk. These findings suggest potential targets for risk stratification and prophylactic strategies, though observed multivitamin associations require prospective validation with attention to confounding before clinical implementation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.